Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more
Adlai Nortye Ltd. American Depositary Shares (ANL) - Net Assets
Latest net assets as of June 2025: $7.92 Million USD
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has net assets worth $7.92 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($72.05 Million) and total liabilities ($64.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.92 Million |
| % of Total Assets | 10.99% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Adlai Nortye Ltd. American Depositary Shares - Net Assets Trend (2019–2024)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adlai Nortye Ltd. American Depositary Shares (2019–2024)
The table below shows the annual net assets of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $25.48 Million | -67.90% |
| 2023-12-31 | $79.40 Million | +132.91% |
| 2022-12-31 | $-241.29 Million | -30.13% |
| 2021-12-31 | $-185.43 Million | -40.95% |
| 2020-12-31 | $-131.56 Million | -89.62% |
| 2019-12-31 | $-69.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adlai Nortye Ltd. American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34269655500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.04% |
| Other Comprehensive Income | $-4.54 Million | -17.79% |
| Other Components | $459.33 Million | 1802.34% |
| Total Equity | $25.48 Million | 100.00% |
Adlai Nortye Ltd. American Depositary Shares Competitors by Market Cap
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mirrabooka Investments Ltd
AU:MIR
|
$350.93 Million |
|
Shandong Yuma Sun-shading Technology Corp. Ltd.
SHE:300993
|
$350.98 Million |
|
Saimo Electric Co Ltd
SHE:300466
|
$351.06 Million |
|
Guizhou Transp Planning
SHG:603458
|
$351.27 Million |
|
Mengtian Home Group Inc.
SHG:603216
|
$350.89 Million |
|
SRG Global Limited
PINK:SRGGF
|
$350.89 Million |
|
Hota Industrial Mfg. Co Ltd
TW:1536
|
$350.88 Million |
|
Zhejiang Whwh
SHG:600576
|
$350.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adlai Nortye Ltd. American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 79,403,015 to 25,485,000, a change of -53,918,015 (-67.9%).
- Net loss of 51,895,016 reduced equity.
- Other comprehensive income decreased equity by 294,000.
- Other factors decreased equity by 1,728,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-51.90 Million | -203.63% |
| Other Comprehensive Income | $-294.00K | -1.15% |
| Other Changes | $-1.73 Million | -6.78% |
| Total Change | $- | -67.90% |
Book Value vs Market Value Analysis
This analysis compares Adlai Nortye Ltd. American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-8.18 | $8.02 | x |
| 2020-12-31 | $-15.51 | $8.02 | x |
| 2021-12-31 | $-21.87 | $8.02 | x |
| 2022-12-31 | $-28.45 | $8.02 | x |
| 2023-12-31 | $11.67 | $8.02 | x |
| 2024-12-31 | $2.39 | $8.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adlai Nortye Ltd. American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -203.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.80x
- Recent ROE (-203.63%) is below the historical average (-55.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.89 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.22 Million |
| 2021 | 0.00% | -123.95% | 0.35x | 0.00x | $-38.14 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.66 Million |
| 2023 | -132.07% | -2099.25% | 0.04x | 1.64x | $-112.81 Million |
| 2024 | -203.63% | 0.00% | 0.00x | 2.80x | $-54.44 Million |
Industry Comparison
This section compares Adlai Nortye Ltd. American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $7.92 Million | 0.00% | 8.10x | $350.92 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |